Brief: Odonate Therapeutics Announces Discontinuation Of Development Of Tesetaxel
22/03/2021 12:02
March 22 (Reuters) - Odonate Therapeutics Inc ODT.O :
* ODONATE THERAPEUTICS ANNOUNCES DISCONTINUATION OF
DEVELOPMENT OF
TESETAXEL
* ODONATE THERAPEUTICS INC - FOLLOWING FEEDBACK FROM U.S.
FDA,
CONCLUDED THAT CLINICAL DATA PACKAGE FOR TESETAXEL IS UNLIKELY
TO SUPPORT FDA APPROVAL
* ODONATE THERAPEUTICS INC - DISCONTINUING DEVELOPMENT OF
TESETAXEL AND WILL WIND DOWN OPERATIONS OF COMPANY
Source text for Eikon: ID:nBw8M4YZqa
Further company coverage: ODT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Odonate
See all newsBrief: Odonate Announces Expected Delisting Of Its Stock
Brief: Odonate Therapeutics Announces Planned Return Of Capital To Stockholders Through Share Repurchase Plan
Brief: Odonate Therapeutics Announces Quarterly Loss Per Share Of $0.58
Odonate Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Odonate Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview